A panel of biopharmaceutical leaders convened at the Galien Forum discussed the impacts of the Inflation Reduction Act so far ...

Michael McDonnell is retiring as CFO of Biogen on Feb. 28, and Chris Viehbacher’s crew has lined up chief accounting officer ...

Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its ...

Biogen shares were off about 4% at $277.10 in ... immunology and rare diseases through deals and partnerships, the new CEO said, and will be looking to cut costs. “I tell people well, there ...

Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of ...

Biogen raised annual profit forecast and beat third-quarter profit expectations on Wednesday, as its cost-cutting measures ...

Neomorph CEO, co-founder and president Phil Chamberlain stated: "Neomorph's molecular glue degrader platform represents a ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

On the “anniversary” of Leqembi’s broader launch last fall, Biogen CEO Chris Viehbacher said the company has already learned a great deal about what it will take for Leqembi to succeed ...

Biogen raised its annual profit forecast and exceeded expectations for third-quarter profit on Wednesday, as new treatments ...